Pasithea Therapeutics CEO sells shares worth $792

May 15, 2025

[
Pasithea Therapeutics CEO sells shares worth $792
[og_img]
https://www.investing.com/news/insider-trading-news/pasithea-therapeutics-ceo-sells-shares-worth-792-93CH-4046693

Investing.com

Montather Rassoul https://thefifthskill.com/

Latest articles

Oil falls more than 1% on expectations for US-Iran nuclear deal

Q4 results today: JSW Energy, PB Fintech among 134 companies to announce earnings on Thursday

These are the 7 best fitness apps for Android (that aren’t Strava)

New Kioxia 332-layer NAND tops out at 2Tb, bigger SSDs planned without the need for PLC

Survival Kids review: a vibrant co-op adventure that lacks meaningful depth

Amazon has a massive sale on Apple devices – AirPods, iPads and MacBooks from $99

Ex-Israeli Intelligence Official: Shockwaves of Trump’s “Take Over Gaza” Heard, Felt Across Region

What UK political parties are promising in the 2019 general election

Otto Warmbier’s parents want North Korea to suffer for their son’s death

Could a ‘youthquake’ cause Boris Johnson to lose the general election?

Which Celebrity Styles Americans Copy Most in 2025: New Study

New ‘Westworld’ trailer introduces us to another dystopian tech company

What’s the point of ‘Charlie’s Angels’ without Sam Rockwell dancing?

These striking photos capture the future of human flight

Judge rejects release of pro-Palestinian activist Khalil

Allogene's SWOT analysis: stock outlook amid clinical delays, promising data

Trump clears path for Nippon Steel investment in US Steel, so long as the Japanese firm complies with a ‘national security agreement’

Legend Biotech's SWOT analysis: carvykti's strong performance drives stock potential

The YouTuber who has become one of Gen Z’s most beloved celebrities

26 last-minute holiday gifts that are still thoughtful and unique

Practicing gratitude regularly can make you less stressed and sleep better

8 things millennials wish you would just stop getting them for the holidays

Pasithea Therapeutics CEO sells shares worth $792

Judge rejects release of pro-Palestinian activist Khalil

These are the 7 best fitness apps for Android (that aren’t Strava)

Allogene's SWOT analysis: stock outlook amid clinical delays, promising data

Trump clears path for Nippon Steel investment in US Steel, so long as the Japanese firm complies with a ‘national security agreement’